|Previous Section||Index||Home Page|
Mr. McGrady: To ask the Secretary of State for Northern Ireland what percentage of electricity was obtained from renewable energy sources by public sector buildings in Northern Ireland in (a) 2003, (b) 2004 and (c) 2005. 
|31 March 2003||7|
|31 March 2004||24|
|31 March 2005||28|
Mr. Peter Robinson: To ask the Secretary of State for Northern Ireland how many speeding fines in Belfast's (a) East, (b) South, (c) West and (d) North district command units remained unpaid in the last year for which figures are available. 
|District Command Unit||Number of unpaid speeding fines|
Angela E. Smith: Information on the number of jobs created in the tourism sector is not available. However, figures from the Quarterly Employment Survey (QES) can be used to estimate the net change in employee jobs. Latest figures from the September 2005 QES estimated that there were 51,290 employee jobs in sectors related to tourism and leisure activities in Northern Ireland. This represented a net increase of 950 jobs from the figure for September 2004.
|Net increase/decrease from previous year|
Dr. Stoate: To ask the Secretary of State for Health what assessment has been made of the (a) safety and (b) efficacy of memantine for use with moderately severe to severe Alzheimer's disease patients; and if she will make a statement. 
Jane Kennedy: Memantine was approved for marketing throughout the European Community in May 2002 under the brand names Axura and Ebixa for the treatment of patients with moderately severe to severe Alzheimer's disease. This regulatory approval was based on evidence of satisfactory product quality, safety and efficacy and that the benefit/risk profile of the product was favourable when treating this disease.
The approval process was carried out by teams of experts within the European Committee for Proprietary Medicinal Products under a community regulatory procedure and lead by experts from Spain and Portugal.
Dr. Stoate: To ask the Secretary of State for Health whether the method of measuring quality of life undertaken by the National Institute for Health and Clinical Excellence for patients with Alzheimer's disease is based on a scale that has been validated for use in people with dementia. 
Jane Kennedy: The National Institute for Health and Clinical Excellence (NICE) uses a standardised and validated generic (non-disease specific) method for its technology appraisals in order to make direct comparisons between outcomes of various treatments for patients with different health problems.
The methods NICE follows for developing its guidance are set out in its Guide to the Methods of Technology Appraisals", and consults regularly on these methods with stakeholders including organisations representing health care professionals and patients. The guidance is available on NICE'S website at www.nice.org.uk.
The National Institute for Health and Clinical Excellence (NICE) issued guidance to the national health service in January 2001 on the use of three drugsAricept, Exelon and Reminyl for the treatment of mild to moderate Alzheimer's disease.
2 Mar 2006 : Column 902W
NICE recommended that these three drugs should be made available to the NHS as one component of the management of people with mild to moderate Alzheimer's disease.
NICE'S consultation on revised draft guidance following a routine review of the effectiveness of these drugs ended on 13 February and they are now in the process of considering the responses. Until NICE issues final guidance to the NHS, the original 2001 guidance on anti-dementia drugs remains extant.
Mr. Stewart Jackson: To ask the Secretary of State for Health how many violent incidents there have been involving staff of the East Anglian Ambulance Service in the course of their duties in each of the last five years. 
Ms Rosie Winterton: A table outlining the estimated number of reported violent incidents collected by the Department for 200001, 200102, 200203 for each strategic health authority (SHA), national health service trust and primary care trust (PCT) in England is available in the Library.
Mrs. Hodgson: To ask the Secretary of State for Health what estimate she has made of the additional pathology capacity which would be necessary to test all women diagnosed with early stage breast cancer for HER2 status. 
Ms Rosie Winterton:
The number of medical and non-medical staff as at 30 September 2004, the latest data available, within the audiological medicine speciality within Bedfordshire and Hertfordshire strategic health authority (SHA), by organisation is shown in the following table.
2 Mar 2006 : Column 903W
|Qualified non-medical staff||All medical staff||Consultant||Associate|
|Bedfordshire and Hertfordshire||30||3||2||1|
|National health service trust||5||0||0||0|
|East and North Hertfordshire NHS trust||13||2||2||0|
|Hertfordshire Partnership NHS trust||1||1||0||1|
|Luton and Dunstable hospital NHS trust||3||0||0||0|
|Luton primary care trust||3||0||0||0|
|West Hertfordshire hospitals NHS trust||5||0||0||0|
|Next Section||Index||Home Page|